Preclinical Pharmacology of CW002

Anesthesiology

Volumn 125, Issue 4, 2016, Pages 732-743

  Sunaga, Hiroshi ^a,f   Savarese, John J ^a   McGilvra, Jeff D ^b   Heerdt, Paul M ^a   Belmont, Matthew R ^a   Van Ornum, Scott G ^c   Murrell, Matthew T ^a   Malhotra, Jaideep K ^a   Savard, Peter M ^a   Jeannotte, Erin ^d   Petty, Bryce J ^a   Allen, Erica ^a   Carnathan, Gilbert W ^a,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Cedarburg Pharmaceuticals   (United States)

^c Department of Pharmaceutical Sciences   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e Pharmaceutical Development Services   (United States)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CW 002; CYSTEINE; NEUROMUSCULAR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CAT; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DEGRADATION; DRUG EFFICACY; DRUG SAFETY; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MUSCLE TWITCH; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SYMPATHETIC REFLEX; VAGUS REFLEX;

EID: 84979986884     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001254     Document Type: Article

References (36)

1. Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM: Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology 2010; 113:58-73
2. Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM: Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: Pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology 2010; 112:900-9
3. Heerdt PM, Malhotra JK, Pan BY, Sunaga H, Savarese JJ: Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. Anesthesiology 2010; 112:910-6
4. Sunaga H, Zhang Y, Savarese JJ, Emala CW: Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology 2010; 112:892-9
5. Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ: Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care 2009; 24:50-7
6. Murrell MT, Savarese JJ: Chapter 52: New vistas in neuromuscular blockers, Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Edited by Kaye AD, Kaye MM, Urman RD. New York, Springer, 2014, pp 827-35
7. Heerdt PM, Sunaga H, Savarese JJ: Novel neuromuscular blocking drugs and antagonists. Curr Opin Anaesthesiol 2015; 28:403-10
8. Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB: Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: A comparison with mivacurium. Anesthesiology 2004; 100:835-45
9. Naguib M, Lien CA: Chapter 13: Pharmacology of muscle relaxants and their antagonists, Miller's Anesthesia, 6th edition. Edited by Miller RD. Philadelphia: Elsevier Churchill Livingstone, 2005, pp 511 and 520
10. Giustarini D, Dalle-Donne I, Lorenzini S, Milzani A, Rossi R: Age-related influence on thiol, disulfide, and protein-mixed disulfide levels in human plasma. J Gerontol A Biol Sci Med Sci 2006; 61:1030-8
11. Aebi S, Assereto R, Lauterburg BH: High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e) ine in plasma and urine. Eur J Clin Invest 1991; 21:103-10
12. Peeters PA, van den Heuvel MW, van Heumen E, Passier PC, Smeets JM, van Iersel T, Zwiers A: Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: A randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig 2010; 30:867-74
13. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR: Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83:1065-71
14. Welch RM, Brown A, Ravitch J, Dahl R: The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995; 58:132-42
15. Magorian TT , Lynam DP, Caldwell JE, Miller RD: Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology 1990; 73:410-4
16. Groudine SB, Soto R, Lien C, Drover D, Roberts K: A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104:555-62
17. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J: Reversal of rocuroniuminduced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006; 104:667-74
18. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM: Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: Efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106:935-43
19. Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS: Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. Anesthesiology 2008; 109:188-97
20. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M: Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: A comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110:1020-5
21. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, Zaremba S, Ayata C, Zhang B, Ma D, Isaacs L, Eikermann M: Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology 2013; 119:317-25
22. Miller RD, Eger EI, Stevens WC: Pancuronium-induced tachycardia in relation to alveolar halothane, dose of pancuronium, and prior atropine. Anesthesiology 1975; 42:332-55
23. Marshall IG, Gibb AJ, Durant NN: Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat. Br J Anaesth 1983; 55:703-14
24. Muir AW, Houston J, Green KL, Marshall RJ, Bowman WC, Marshall IG: Effects of a new neuromuscular blocking agent (Org 9426) in anaesthetized cats and pigs and in isolated nerve-muscle preparations. Br J Anaesth 1989; 63:400-10
25. Stevens JB, Hecker RB, Talbot JC, Walker SC: The haemodynamic effects of rocuronium and vecuronium are different under balanced anaesthesia. Acta Anaesthesiol Scand 1997; 41:502-5
26. Wastila WB, Maehr RB, Turner GL, Hill DA, Savarese JJ: Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats. Anesthesiology 1996; 85:169-77
27. Kron SS: Severe bronchospasm and desaturation in a child associated with rapacuronium. Anesthesiology 2001; 94:923-4
28. Meakin GH, Pronske EH, Lerman J, Orr R, Joffe D, Savaree AM, Lynn AM: Bronchospasm after rapacuronium in infants and children. Anesthesiology 2001; 94:926-7
29. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology 1998; 88:744-50
30. Jooste E, Klafter F, Hirshman CA, Emala CW: A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. Anesthesiology 2003; 98:906-11
31. Jooste E, Zhang Y, Emala CW: Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle. Anesthesiology 2005; 102:117-24
32. Jooste EH, Sharma A, Zhang Y, Emala CW: Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology 2005; 103:1195-203
33. Jooste E, Zhang Y, Emala CW: Neuromuscular blocking agents' differential bronchoconstrictive potential in Guinea pig airways. Anesthesiology 2007; 106:763-72
34. Heerdt PM, Kang R, The' A, Hashim M, Mook RJ Jr, Savarese JJ: Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology 2004; 100:846-51
35. Savarese JJ, Ali HH, Basta SJ, Scott RP, Embree PB, Wastila WB, Abou-Donia MM, Gelb C: The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology 1989; 70:386-94
36. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ: Clinical pharmacology of GW280430A in humans. Anesthesiology 2004; 100:768-73